Modulation of the miR-485-3p/PGC-1α Pathway by ASO-Loaded Nanoparticles Attenuates ALS Pathogenesis

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Amyotrophic Lateral Sclerosis (ALS) is a fatal neurodegenerative disease with limited treatments.
• Motor neuron degeneration is a hallmark of ALS, impacting mitochondrial function and neuroprotection.
• MicroRNAs play a role in neurodegenerative diseases, but their specific function in ALS requires further investigation.

Purpose of the Study:

• To investigate the role of microRNA-485-3p (miR-485-3p) in ALS pathogenesis.
• To explore the regulation of PGC-1α by miR-485-3p in the context of ALS.
• To evaluate the therapeutic potential of BMD-001S, a novel antisense oligonucleotide formulation, for ALS treatment.

Main Methods:

• Assessed miR-485-3p expression in SOD1^G93A microglial cells and transgenic mouse spinal cords.
• Administered BMD-001S intravenously to SOD1^G93A mice.
• Measured PGC-1α mRNA and protein levels, SOD1 aggregation, neuroinflammation markers, and neurofilament light chain (NfL) in cerebrospinal fluid.
• Evaluated electrophysiological parameters and neuromuscular junction integrity.

Main Results:

• miR-485-3p expression was significantly elevated in ALS models.
• BMD-001S treatment reduced miR-485-3p levels and restored PGC-1α expression.
• Therapeutic effects included reduced SOD1 aggregation, decreased neuroinflammation, and lower NfL levels.
• BMD-001S improved electrophysiological function and preserved neuromuscular junctions.

Conclusions:

• The miR-485-3p/PGC-1α pathway is implicated in ALS pathogenesis.
• BMD-001S demonstrates therapeutic potential by targeting miR-485-3p.
• This study supports BMD-001S as a promising novel treatment strategy for ALS.